SciRhom
Key Facts
| Invested since | 2016 |
| Based in | Bavaria |
About the company
SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.
Do you want to
know more about this company?
SciRhom in the news
Zum Artikel
Against the tide – HTGF portfolio SciRhom company rewarded for courage with EUR 63 million Series A financing
Zum Artikel
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.
More startups from Life Sciences
Hamburg-based COLIPI is developing an industrial biotechnological process that transforms climate-damaging CO2 and carbon-containing industrial waste into Climate Oil. This product serves as a sustainable and climate-neutral alternative to palm …
To the complete profileof COLIPI
Nuuron was founded by Fabian Queisner and Dr. Markus Müschenich. The scientific director is Priv.-Doz. Dr. Julian Keil. The Nuuron team consists of experts in the fields of neuroscience, medicine, …
To the complete profileof Nuuron
Exit
The founders of Kumovis GmbH have set themselves the goal of enabling the additive production of plastic implants and are developing innovative 3D printers specifically for medical products. Kumovis focuses …
To the complete profileof Kumovis
Exit
KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare. Exit since Feb. 2011. Purchaser: Evotec AG
To the complete profileof KINAXO
Exit
650 million people suffer from mental illness like depression, anxiety or burnout worldwide. Even in developed countries there is a huge treatment gap: 50% do not get treated. Selfapy offers …
To the complete profileof Selfapy
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC). Alentis has in-licensed platform technologies and monoclonal …
To the complete profileof Alentis
Exit
Fiagon develops a new medical navigation system for intraoperative process control and positioning of instruments for ENT, head-/ neck- and neurosurgery.
To the complete profileof Fiagon
Symphera is a Munich-based startup that is revolutionizing laparoscopic surgery with an innovative system designed to eliminate the need for manual instrument changes. Founded in 2023, Symphera was incubated at …
To the complete profileof Symphera
Exit
GILUPI developed a nanostructured detector, which is temporarily inserted into the bloodstream. The aim is to spot specific blood cells in vivo and thus to detect diseases in a very …
To the complete profileof GILUPI
Exit
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …
To the complete profileof Emergence Therapeutics
GS Bavaria is the world‘s first supplier of nano- hard metal materials on industrial scale. Production is extremely cost-efficient, sustainable and comes with minimal energy consumption through our unique bioleaching …
To the complete profileof GS Bavaria
Verovaccines is a biopharmaceutical company developing combination vaccines for animal health using a new proprietary technology. These vaccines offer several solutions for medical and industry needs in animal health: new …
To the complete profileof VEROVACCiNES